Literature DB >> 10508617

Ubiquitin-dependent degradation of active Src.

Y Hakak1, G S Martin.   

Abstract

Signaling by members of the Src family of protein tyrosine kinases, such as Src and Fyn, is important in many biological responses, including gene transcription, cell-cycle progression, and cell adhesion and spreading [1] [2]. Unregulated Src kinase activity has been implicated in the progression of colon cancer and transformation of cultured cells [3] [4] [5] [6]. Thus, precise regulation of Src activity is critical for normal cell growth. Src kinase activity is downregulated by the carboxy-terminal Src kinase (Csk), a tyrosine kinase that phosphorylates a conserved tyrosine residue in the carboxy-terminal tail of Src [7] [8]. When phosphorylated, this tyrosine residue mediates an intramolecular interaction that results in a 'closed' or inactive conformation [1] [2] [9] [10]. Here, we report that loss of csk resulted in a reduction in the abundance of the Src and Fyn proteins, which could be restored by reintroducing catalytically active Csk. The effect of Csk on Src expression was not due to an increase in Src message, but to stabilization of the Src protein. Inhibition of proteasome activity also increased the level of Src protein in csk-deficient cells. Src was found to be ubiquitinated, and activation of Src increased the extent of polyubiquitination. Thus, ubiquitin-proteasome-dependent degradation represents an additional mechanism by which active Src can be downregulated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508617     DOI: 10.1016/s0960-9822(99)80453-9

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  43 in total

1.  The design of a hyperstable mutant of the Abp1p SH3 domain by sequence alignment analysis.

Authors:  A Rath; A R Davidson
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

2.  Lys48-linked TAK1 polyubiquitination at lysine-72 downregulates TNFα-induced NF-κB activation via mediating TAK1 degradation.

Authors:  Yihui Fan; Yi Shi; Shangfeng Liu; Renfang Mao; Lei An; Yanling Zhao; Hong Zhang; Fuchun Zhang; Guotong Xu; Jun Qin; Jianhua Yang
Journal:  Cell Signal       Date:  2012-03-03       Impact factor: 4.315

3.  Regulation of expression and function of Lck tyrosine kinase by high cell density.

Authors:  Patricia Ozegbe; Yuti Chernajovsky; Panagiotis S Kabouridis
Journal:  Mol Membr Biol       Date:  2005 Jul-Aug       Impact factor: 2.857

Review 4.  Degradation of activated protein kinases by ubiquitination.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

5.  An essential role of ubiquitination in Cbl-mediated negative regulation of the Src-family kinase Fyn.

Authors:  Navin Rao; Amiya K Ghosh; Patrice Douillard; Christopher E Andoniou; Pengcheng Zhou; Hamid Band
Journal:  Signal Transduct       Date:  2002-11-07

Review 6.  Cell regulation by phosphotyrosine-targeted ubiquitin ligases.

Authors:  Jonathan A Cooper; Tomonori Kaneko; Shawn S C Li
Journal:  Mol Cell Biol       Date:  2015-03-16       Impact factor: 4.272

7.  A glycosphingolipid/caveolin-1 signaling complex inhibits motility of human ovarian carcinoma cells.

Authors:  Alessandro Prinetti; Ting Cao; Giuditta Illuzzi; Simona Prioni; Massimo Aureli; Nicoletta Gagliano; Giovanni Tredici; Virginia Rodriguez-Menendez; Vanna Chigorno; Sandro Sonnino
Journal:  J Biol Chem       Date:  2011-09-23       Impact factor: 5.157

8.  Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformation.

Authors:  Anjali Teckchandani; George S Laszlo; Sergi Simó; Khyati Shah; Carissa Pilling; Alexander A Strait; Jonathan A Cooper
Journal:  J Cell Sci       Date:  2013-11-27       Impact factor: 5.285

9.  Restriction of Src activity by Cullin-5.

Authors:  George S Laszlo; Jonathan A Cooper
Journal:  Curr Biol       Date:  2009-01-15       Impact factor: 10.834

10.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

Authors:  Y-M Chang; L Bai; S Liu; J C Yang; H-J Kung; C P Evans
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.